Phibro Animal Health Corp (PAHC) — SEC Filings
Phibro Animal Health Corp (PAHC) — 34 SEC filings. Latest: 8-K (Dec 18, 2025). Includes 16 8-K, 5 SC 13G/A, 4 10-Q.
View Phibro Animal Health Corp on SEC EDGAR
Overview
Phibro Animal Health Corp (PAHC) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 18, 2025: Phibro Animal Health Corporation filed an 8-K on December 18, 2025, reporting on events that occurred on December 16, 2025. The filing covers the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain offi
Sentiment Summary
Across 34 filings, the sentiment breakdown is: 3 bullish, 31 neutral. The dominant filing sentiment for Phibro Animal Health Corp is neutral.
Filing Type Overview
Phibro Animal Health Corp (PAHC) has filed 16 8-K, 4 10-Q, 2 DEF 14A, 2 10-K, 1 8-K/A, 2 SC 13D/A, 5 SC 13G/A, 2 SC 13G with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (34)
Risk Profile
Risk Assessment: Of PAHC's 25 recent filings, 0 were flagged as high-risk, 10 as medium-risk, and 15 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $363.9M |
| Net Income | $26.5M |
| EPS | $0.65 |
| Debt-to-Equity | 0.99 |
| Cash Position | $72.8M |
| Operating Margin | 14.1% |
| Total Assets | $1.39B |
| Total Debt | $732.96M |
Key Executives
- Jack C. Bendheim
- Alejandro Bernal
- E. Thomas Corcoran
- Judith A. Weinstein
- Anthony Andolino
- Dr. David L. MacGregor
- Mr. David M. Johnson
- J. Scott Henry
- Deanne K. R. Smith
- Dr. H. Steven B. Smith
- Dr. David L. Urban
Industry Context
Phibro operates in the global animal health and mineral nutrition market, serving food and companion animals. The industry is characterized by increasing demand for animal protein, a focus on animal welfare, and the ongoing need for disease prevention and treatment solutions. Competition is significant, with major players investing heavily in R&D and strategic acquisitions to expand their portfolios and market reach.
Top Tags
financials (4) · 8-k (4) · amendment (4) · 10-Q (3) · sec-filing (3) · financial-reporting (3) · 8-K (3) · institutional-ownership (3) · corporate-governance (2) · Animal Health (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Sales | $363.9M | Increased 39.7% from $260.4M in Q1 2024 |
| Net Income | $26.5M | Increased 280% from $7.0M in Q1 2024 |
| Diluted EPS | $0.65 | Increased from $0.17 in Q1 2024 |
| Acquisition Revenue | $80.5M | Revenue from Zoetis acquisition in Q1 2025 |
| Operating Income | $51.3M | Increased from $17.7M in Q1 2024 |
| Interest Expense, net | $12.1M | Increased from $7.6M in Q1 2024 |
| Foreign Currency Losses, net | $2.9M | Increased from $0.4M in Q1 2024 |
| Cash and Cash Equivalents | $72.8M | As of September 30, 2025, up from $68.0M at June 30, 2025 |
| Zoetis Acquisition Purchase Price | $297.5M | Funded by Delayed Draw Term A-1 and A-2 Loans |
| Net Sales Growth | 39.7% | Year-over-year increase for the three months ended September 30, 2025 |
| Shares of Class A common stock outstanding | 20,367,574 | As of the Record Date, September 12, 2025 |
| Shares of Class B common stock outstanding | 20,166,034 | As of the Record Date, September 12, 2025 |
| Start time of the Annual Meeting | 9:00 A.M. Eastern Time | On Tuesday, November 4, 2025 |
| Date of the Annual Meeting | November 4, 2025 | Stockholders will vote on key proposals |
| Record Date for voting eligibility | September 12, 2025 | Only stockholders of record on this date can vote |
Forward-Looking Statements
- {"claim":"Other institutional investors may take a closer look at Phibro Animal Health Corp due to Pzena's significant stake.","entity":"Phibro Animal Health Corp","targetDate":"Next 3-6 months","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Phibro Animal Health Corp (PAHC)?
Phibro Animal Health Corp has 34 recent SEC filings from Jan 2024 to Dec 2025, including 16 8-K, 5 SC 13G/A, 4 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PAHC filings?
Across 34 filings, the sentiment breakdown is: 3 bullish, 31 neutral. The dominant sentiment is neutral.
Where can I find Phibro Animal Health Corp SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Phibro Animal Health Corp (PAHC) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Phibro Animal Health Corp?
Key financial highlights from Phibro Animal Health Corp's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PAHC?
The investment thesis for PAHC includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Phibro Animal Health Corp?
Key executives identified across Phibro Animal Health Corp's filings include Jack C. Bendheim, Alejandro Bernal, E. Thomas Corcoran, Judith A. Weinstein, Anthony Andolino and 6 others.
What are the main risk factors for Phibro Animal Health Corp stock?
Of PAHC's 25 assessed filings, 0 were flagged high-risk, 10 medium-risk, and 15 low-risk.
What are recent predictions and forward guidance from Phibro Animal Health Corp?
Recent forward-looking statements from Phibro Animal Health Corp include guidance on {"claim":"Other institutional investors may take a closer look at Phibro Animal Health Corp due to Pzena's significant s.